LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq: SVA) concerning possible violations of federal securities laws between April 30, 2013 and May 16, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the September 1, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at firstname.lastname@example.org.
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO Weidong Yin bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; that such conduct would subject the Company to heightened regulatory scrutiny; and that as a result of the above, Sinovac’s public statements were materially false and misleading at all relevant times. Upon release of this news, shares of Sinovac fell in value materially, which caused investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.